Diagnostic Value of the Biofire®in Community Acquired Pneumonia
NCT ID: NCT06428318
Last Updated: 2024-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2023-05-15
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Phase Reactant in Non-COVID-19 Bacterial Pneumonia
NCT05926089
Use of a Rapid Diagnostic Test for Antibiotic De-escalation in Severe Community Acquired Pneumonia
NCT04781829
Molecular vs Conventional Microbiologic Diagnosis for Infections in Lung Transplantation
NCT05960383
FilmArray Pneumonia Panel for Antimicrobial Treatment of HAP/VAP in Intensive Care Units
NCT05214716
Diagnosis of Lower Respiratory Tract Infections Using Biofire Filmarray
NCT04283422
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study compare the diagnostic accuracy, turnaround time, and impact on antibiotic management decisions of BFPP versus conventional sputum culture in critically ill patients admitted to the ICU with suspected pneumonia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: Routine Conventional Methods
Patients subjected to Routine sputum culture Conventional Methods
Conventional Sputum culture
Sputum culture was done to patients and they received Antibiotics According to its results
GroupB: BioFire Pneumonia Panel (BFPP).
Patients subjected to BioFire Pneumonia Panel (BFPP
BioFire Pneumonia Panel (BFPP)
BioFire Pneumonia Panel (BFPP) was done to patients and they received Antibiotics According to its results
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Conventional Sputum culture
Sputum culture was done to patients and they received Antibiotics According to its results
BioFire Pneumonia Panel (BFPP)
BioFire Pneumonia Panel (BFPP) was done to patients and they received Antibiotics According to its results
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* End stage malignant patients,
* Patients admitted to the ICU with Acute Lung Injury (ALI).
* Patients admitted to the ICU with Acute Respiratory Distress Syndrome (ARDS).
* Patients with radiological findings suggesting atypical pneumonia.
* Immunocompromised as defined by HIV/AIDS, known immunodeficiency, chronic steroids \> 20mg/day Prednisone equivalent, other immunosuppressants.
* Solid organ or bone marrow transplant patients, cystic fibrosis.
* Unstable psychiatric or psychological condition rendering the subject unlikely to be cooperative or to complete the study requirements.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rania Maher Hussien, MD
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University
Cairo, Abassia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU MS267/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.